1results about How to "Has weight loss effect" patented technology

This invention discloses a dual-activator polypeptide compound and its pharmaceutical uses, belonging to the field of polypeptide pharmaceuticals. The amino acid sequence of the GIP-R and GLP-1R dual-activator polypeptide compound is: Y-Z-EGTFTSDYSI-X2-LDKI-A-Q-B n -X4-X5-VQWLI-X6-GGPSSG-A-PPPS, with the C-terminal amino acid being amidated. The GIP-R and GLP-1R dual-agonist polypeptide compounds of this invention exhibit more significant dual-agonist activity against human glucose-dependent insulinotropic peptide (GIP) and human glucagon-like peptide-1 (GLP-1) receptors. They not only possess hypoglycemic and weight-loss effects but also have a longer half-life and higher bioavailability, avoiding adverse reactions such as nausea and vomiting caused by long-term use of existing drugs. They can be used as effective raw materials for preparing drugs for treating or preventing diabetes or weight-loss drugs.